| Sign In to gain access to subscriptions and/or personal tools. |
The long-term management of depressionInternational Pharmaceuticals, Pfizer Inc., 235 East 42nd St, New York, NY 10017, USA The long-term outlook for patients with unipolar depression is often poor. As few as one-fifth will remain well and a similar number will suffer chronic depression. It is now standard practice to extend acute treatment into a 4-6 month period of continuation therapy, and the value of prophylactic treatment over longer periods is becoming more widely recognised. Care must, however, be exercised in choosing suitable long-term treatment. Relatively little work on the prophylactic efficacy of the tricyclic antidepressants has been carried out, although imipramine has been shown to be effective. The selective serotonin re-uptake inhibitors (SSRIs) have been studied extensively and may be the most suitable long-term treatment for depression. Sertraline is effective in preventing both relapse and recurrence of depression and was the first agent specifically indicated for the long-term treatment of depression in the UK. In addition to clinical efficacy, many other factors favour SSRIs in the long-term management of depression. The tolerability of a drug is of major importance in long-term therapy since it affects compliance. Other important considerations include toxicity, safety in overdose, drug interaction potential, psychomotor effects and accident liability.
Key Words: depression continuation treatment • maintenance treatment • SSRI • sertraline • relapse • recurrence
Journal of Psychopharmacology, Vol. 9, No. 2 suppl,
191-198 (1995) |
|||
 |
|
|
 |
Sign In to gain access to subscriptions and/or personal tools.
